gw1100 has been researched along with Hypoglycemia* in 1 studies
1 other study(ies) available for gw1100 and Hypoglycemia
Article | Year |
---|---|
Curcumin improves glucose tolerance via stimulation of glucagon-like peptide-1 secretion.
Glucagon-like peptide-1 (GLP-1) is a type of incretin secreted from enteroendocrine L-cells. Our previous studies demonstrated that curcumin (a yellow pigment of turmeric) significantly increases the secretion of GLP-1 in enteroendocrine L cell line (GLUTag cells). However, it is not clear whether its action in vivo directly enhances GLP-1 secretion, which then leads to a reduction in blood glucose levels via the stimulation of insulin secretion. In addition, the molecular target of curcumin-induced GLP-1 secretion has not been clarified.. Glucose tolerance was significantly improved in rats after pre-administered curcumin (1.5 mg/kg) followed by intraperitoneal glucose injections via the stimulation of GLP-1 secretion and the induction of insulin secretion. In GLUTag cells, curcumin-induced GLP-1 secretion was associated with G protein-coupled receptor (GPR) 40/120. Furthermore, the glucose-lowering effect induced by curcumin was significantly reduced after the administration of a GPR40/120 antagonist in rats.. These findings demonstrate the biological function of curcumin as a GLP-1 secretagogue and the possible molecular target that mediates GLP-1 secretion. Increases in the secretion of endogenous GLP-1 induced by curcumin may allow the dosages of other diabetic medicines to be reduced and aid in the prevention of diabetes. Topics: Administration, Oral; Animals; Benzoates; Blood Glucose; Cell Line; Curcumin; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Hypoglycemia; Injections, Intraperitoneal; Insulin; Male; Mice; Pyrimidines; Rats, Sprague-Dawley; Receptors, G-Protein-Coupled | 2017 |